These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26940836)

  • 1. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
    Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
    BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
    Liu R; Zhou J; Xia S; Li T
    Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.
    Wang H; Sun X; Zhao L; Chen X; Zhao J
    J Diabetes Investig; 2016 Jul; 7(4):629-36. PubMed ID: 27181717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
    Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
    PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
    Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
    Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Jespersen CG; Nørgaard M; Borre M
    Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
    Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
    Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
    Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
    JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
    Cui H; Wang Y; Li F; He G; Jiang Z; Gang X; Wang G
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):15-23. PubMed ID: 32814845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.